Drug Trial Radar · NCT07521046
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Aug 2029
Study completion Aug 2030
Sponsor
- Lead sponsor
- University of UtahAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- PharmaEssentia
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Conditions
- Myelofibrosis
Interventions
ropeginterferon alfa- 2bDrug
Ropeginterferon alfa- 2b will be administered as a subcutaneous injection every two weeks.
RuxolitinibDrug
Ruxolitinib will be administered per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by typeTime frame: 2 years
- The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0).Time frame: 2 years
- The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness.Time frame: 2 years
- The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration.Time frame: 2 years
- The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by the relationship to study treatment.Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.